Zetia

Positive phase 3 data on GSP 301; USD 100m opportunity for co: Glenmark

Glenmark Pharma reports positive results from a phase 3 trial of GSP 301, a fixed-dose combination nasal spray.

Glenmark Q3 net soars 143% to Rs 477 cr aided by US generic biz

The US business that constitutes close to half of Glenmark‘s business doubled to Rs.1230.8 crore led by new launches including generic version of Zetia - that has 180-day exclusivity.

Q3 results: Five trends to watch out from Indian drugmakers

Analysts predict Q3 to be a tough quarter with revenue growth moderating to 11.7 percent in October-December period compared to 18.4 percent compounded annual growth rate (CAGR) over last 10 years

New launches to drive earnings growth in FY18 & FY19: Glenmark

The company has a strong pipeline of products which the company, CMD Glenn Saldanha said adding that new launches will drive earnings for the company in FY18 and FY19. The company has no plans to raise further capital, he said.

See EBITDA margins at 25% over 10 years: Glenmark CMD

The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.

Glenmark launches generic version of Zetia in US

Glenmark Pharmaceuticals Inc has announced the availability of ezetimibe, the first and only generic version of Merck's Zetia in the United States.

Glenmark to launch cholesterol drug Zetia in US on Dec 12

Glenmark was the first to file for the generic version of Zetia and it means that after the launch on December 12, only Glenmark and Merck will sell generic Zetia in the US market for the next 6 months.

Zetia generic launch could help Glenmark trim debt: Surajit Pal

Good cash flows from the launch of cholesterol-lowering drug Zetia in December could help Glenmark Pharma trim its debt significantly by the end of the year says Pharma Analyst Surajit Pal of Prabhudas Lilladher. Glenmark will enjoy 134 days of exclusivity from the launch of the drug.